<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03827031</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2017-02/JMK-01</org_study_id>
    <nct_id>NCT03827031</nct_id>
  </id_info>
  <brief_title>Implementation and Impact ofShared Medication Reportin Surgery Department on Medical Care of Elderly Patients in the City</brief_title>
  <acronym>CHIROPMEV</acronym>
  <official_title>Implementation and Impact ofShared Medication Reportin Surgery Department on Medical Care of Elderly Patients in the City</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The presence of a clinical pharmacist (because of his pharmacological expertise) and a
      general practitioner (because of his somatic expertise) would contribute to improving the
      proper use of medicines.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Medication Adverse Event Risk Score</measure>
    <time_frame>Month 3</time_frame>
    <description>The score ranges from 0 to 10. A score of 0-1 refers to a low risk. A score between 2-5 refers to a medium risk. A risk between 6-10 refers to a high risk.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of revision proposals accepted by the attending physician and / or specialist</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average number of inappropriate medications per patient</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of changes accepted by the attending physician on the number of proposed changes</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time required to perform the pharmaceutical report</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of reports sent to the attending physician</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modes of report transmission</measure>
    <time_frame>Month 3</time_frame>
    <description>email, fax or letter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explication détails about the non-transmission of a report</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of reports performed by the dispensary pharmacist</measure>
    <time_frame>month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of reports sent by the dispensary pharmacist to other physicians</measure>
    <time_frame>month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients rehospitalized</measure>
    <time_frame>month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of dead patients</measure>
    <time_frame>month 3</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">297</enrollment>
  <condition>Iatrogenic Disease</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B1 interventional group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B2 interventional group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>revision of the prescription drug</intervention_name>
    <description>The doctor will perform a clinical examination and then exchange in a collaborative interview with the clinical pharmacist; on this basis, the doctor will establish a new out-patient prescription and the pharmacist will perform an exit interview with the patient.</description>
    <arm_group_label>B1 interventional group</arm_group_label>
    <arm_group_label>B2 interventional group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Strengthening the city-hospital link</intervention_name>
    <description>organization of a telephone appointment between the doctor and the attending physician and / or specialist</description>
    <arm_group_label>B2 interventional group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient (or their representative) has given his consent and signed the consent
             form.

          -  The patient is affiliated to a health insurance programme.

          -  The patient is at least 65 years old (≥) with a chronic long-term illness or 75 (≥)
             receiving a treatment for a chronic disease.

          -  The patient is available for a follow-up of 3 months.

          -  The patient is hospitalized in the surgery department.

          -  Patient with chronic drug therapy for a chronic pathology.

          -  Patient with a Trivalle score greater than or equal to 2 (≥).

          -  Patient living in a nursing home or going back home after hospitalization.

        Exclusion Criteria:

          -  The subject is participating in another interventional study.

          -  The subject is in an exclusion period determined by another study.

          -  The subject is under safeguard of justice.

          -  It is not possible to give the patient (or his/her trusted-person) informed
             information.

          -  Palliative care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marie Kinowski</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nîmes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Marie Kinowski</last_name>
    <phone>+33(0)4.66.68.31.04</phone>
    <email>jean.marie.kinowski@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nimes University Hospital</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>+33 (0)4.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Géraldine LEGUELINEL-BLACHE, PharmaD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marie KINOWSKI, PharmaD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène RICHARD, PharmaD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal KOUYOUMDJIAN, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2019</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iatrogenic Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

